Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Maher · SciRah

Researcher profile · Semantic Scholar

K. Maher

Share profile

K. Maher — researcher profile on SciRah

h-index: 7
Works: 101
Citations: 234

Most-cited papers

Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives
I. Bouligny, K. Maher, S. Grant
2022Blood reviews34 citations Open access
Semantic Scholar
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome
K. Maher, D. Shafer, Dale G Schaar, Dipankar Bandyopadhyay +6 more
2025Cancer Chemotherapy and Pharmacology22 citations Open access
Semantic Scholar
Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification
S. Tantravahi, A. Kishtagari, K. Maher, S. Mohan +6 more
2023Blood18 citations
Semantic Scholar
Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
I. Bouligny, Graeme F Murray, Michael Doyel, Tilak Patel +10 more
2023eJHaem18 citations Open access
Semantic Scholar
Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation
Emmanuel Katsanis, K. Maher, D. Roe, R. Simpson
2020eJHaem14 citations Open access
Semantic Scholar
Secondary-Type Mutations in Acute Myeloid Leukemia: Updates from ELN 2022
I. Bouligny, K. Maher, S. Grant
2023Cancers12 citations Open access
Semantic Scholar
Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia
I. Bouligny, Graeme F Murray, Michael Doyel, Tilak Patel +11 more
2024Medical Oncology11 citations Open access
Semantic Scholar
Post-Allogeneic Stem Cell Transplantation Maintenance Dasatinib in Philadelphia Chromosome Positive Acute Leukemia
K. Maher, A. McBride, A. Amaraneni, Onyemaechi N Okolo +2 more
20177 citations Open access
Semantic Scholar
A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS
Amir T. Fathi, Aleksandra Filipovic, K. Maher, Dale G Schaar +10 more
2024Blood6 citations
Semantic Scholar
Augmenting Venetoclax Activity Through Signal Transduction in AML
I. Bouligny, K. Maher, S. Grant
2023Journal of cellular signaling6 citations Open access
Semantic Scholar
Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting
L. Jafari, Jubair Hussain, Ravi Krishnadasan, K. Maher +7 more
2019Blood6 citations
Semantic Scholar
Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)
N. Daver, A. Stein, Dale L. Bixby, W. Chai-Ho +14 more
2023Blood5 citations Open access
Semantic Scholar
Cellular Transplant Therapies for Globoid Cell Leukodystrophy: Preclinical and Clinical Observations
K. Maher, A. Yeager
2016Journal of Neuroscience Research5 citations Open access
Semantic Scholar
Clonal evolution in 207 cases of refractory or relapsed acute myeloid leukemia
Graeme F Murray, I. Bouligny, T. Hồ, J. Gor +4 more
2024European Journal of Haematology4 citations
Semantic Scholar
P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS
H. Ali, A. Kishtagari, K. Maher, S. Mohan +9 more
2022HemaSphere4 citations Open access
Semantic Scholar
Validation of the Charlson Comorbidity Index Model in Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax
I. Bouligny, Graeme F Murray, T. Hồ, J. Gor +4 more
2023Blood3 citations Open access
Semantic Scholar
A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)
K. Maher, R. Rampal, P. Bose, N. Podoltsev +5 more
2023Blood3 citations Open access
Semantic Scholar
Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
I. Bouligny, Graeme F Murray, T. Hồ, Michael Doyel +11 more
2023Research Square3 citations Open access
Semantic Scholar
Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
I. Bouligny, Graeme F Murray, T. Hồ, Michael Doyel +11 more
2023Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis3 citations
Semantic Scholar
Abstract CT261: A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis
H. Ali, A. Kishtagari, K. Maher, Sanjay R. Mohan +5 more
2023Cancer Research3 citations
Semantic Scholar
Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results from XPORT-MF-034.
H. Ali, A. Kishtagari, K. Maher, Sanjay R. Mohan +4 more
2023Journal of Clinical Oncology3 citations
Semantic Scholar
A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis
H. Ali, A. Kishtagari, K. Maher, Sanjay R. Mohan +5 more
2022Blood3 citations
Semantic Scholar
Prevention and management of infections after exposure to ionising radiation
K. Maher, I. Bouligny, A. Yeager
2021Journal of Radiological Protection3 citations
Semantic Scholar
A Case of Myeloid Sarcoma following Allogeneic HSCT Presenting as Localized Hip Pain
Shannon Zhang, C. Charlton, A. Amaraneni, K. Maher
2019Case Reports in Hematology3 citations Open access
Semantic Scholar
A phase I dose escalation and expansion trial of lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) alone and in combination with venetoclax/HMA in Relapsed/Refractory AML/MDS
Aleksandra Filipovic, Amir T. Fathi, N. Merin, K. Maher +6 more
2025Blood2 citations
Semantic Scholar
Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.
John O. Mascarenhas, K. Maher, R. Rampal, P. Bose +5 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar
CUX1 mut Acute Myeloid Leukemia As a Distinct Biological Entity: An Analysis of Clinical Outcomes and Implications
I. Bouligny, Graeme F Murray, T. Hồ, J. Gor +4 more
2023Blood2 citations Open access
Semantic Scholar
Clinical outcomes of core binding factor acute myeloid leukemia in the modern era.
Yiwei Hang, I. Bouligny, Graeme F Murray, Tilak Patel +11 more
2023Journal of Clinical Oncology2 citations
Semantic Scholar
IDH1/2 mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML
I. Bouligny, Graeme F Murray, Valerie Tran, J. Gor +5 more
2022Blood2 citations
Semantic Scholar
Minority Health Disparities in Acute Myeloid Leukemia: A Metropolitan, Single-Center Retrospective Analysis
K. Maher, I. Bouligny
2021Blood2 citations
Semantic Scholar
Outcomes of Induction with Venetoclax in Combination with Decitabine, Azacitidine, or Low-Dose Cytarabine for Treatment of AML: A Real-World Retrospective Analysis
I. Bouligny, K. Maher
2021Blood2 citations Open access
Semantic Scholar
Acute Leukemia of Ambiguous Lineage
M. Sardar, R. Krishnadasan, K. Maher
2020Handbook of Hematologic Malignancies2 citations Open access
Semantic Scholar
Prognostic Role of Microvascular Density and Mucin Production in 56 Cases ofAdenocarcinoma of Lung- An Experience from a Center in Lahore, Pakistan
Ehsan Ullah, A. Nagi, M. Ashraf, A. Pasha +2 more
20162 citations Open access
Semantic Scholar
Toward a Deeper Understanding of Clonal Evolution in Acute Myeloid Leukemia: Translational and Clinical Impacts
K. Maher, Graeme F Murray, T. Hồ, Steven Grant
2025Journal of Cellular Signaling1 citations Open access
Semantic Scholar
A propensity score–matched comparison of cytoreductive strategies in patients with acute myeloid leukemia presenting with hyperleukocytosis.
George Avetian, T. Hồ, Hyun Lee, I. Bouligny +1 more
2024Journal of Clinical Oncology1 citations
Semantic Scholar
Selinexor-Driven Regulation of Proinflammatory Cytokines May Lead to Stabilization of Hematologic Parameters and Bone Marrow Function in Patients with Myelofibrosis: Case Study from the Phase 1 Sentry Trial
H. Ali, K. Maher, A. Kishtagari, S. Mohan +6 more
2024Blood1 citations
Semantic Scholar
IDH inhibitors or chemotherapy in relapsed or refractory IDHmut acute myeloid leukemia.
Graeme F Murray, I. Bouligny, Tilak Patel, Michael Doyel +11 more
2023Journal of Clinical Oncology1 citations
Semantic Scholar
First-Line Venetoclax and a Hypomethylating Agent or Conventional Chemotherapy in Older Adults with IDH-Mutated AML
I. Bouligny, Graeme F Murray, T. Hồ, J. Gor +4 more
2023Blood1 citations
Semantic Scholar
Phase 1b/2 Study of Escalating Doses of the NEDD8 Activating Enzyme Inhibitor Pevonedistat Administered in Combination with Standard Induction Therapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myeloid Leukemia
Carissa M. Feliciano, J. Carew, H. Carraway, J. Watts +16 more
2023Blood1 citations
Semantic Scholar
The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine.
Michael Doyel, I. Bouligny, Graeme F Murray, Tilak Patel +11 more
2023Journal of Clinical Oncology1 citations Open access
Semantic Scholar
POSTER: MPN-336 Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi) Treatment-Naïve Patients With Myelofibrosis: Updated Results and Subgroup Analyses from XPORT-MF-034
Haris Ali, A. Kishtagari, K. Maher, Sanjay R. Mohan +4 more
2023Clinical Lymphoma, Myeloma & Leukemia1 citations Open access
Semantic Scholar
Impact of COVID-19 Pandemic on Overall Survival in Acute Myeloid Leukemia: A Comprehensive Cancer Center Experience of 627 Patients
J. Gor, I. Bouligny, T. Hồ, Graeme F Murray +1 more
2023Blood1 citations Open access
Semantic Scholar
Pevonedistat plus belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome: A phase I multicenter study.
K. Maher, Danielle Schafer, D. Schaar, R. Sabo +2 more
2023Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Impact of Recent Advancements in Relapsed/Refractory Acute Myeloid Leukemia on Overall Survival in Clinical Practice
T. Hồ, J. Gor, Graeme F Murray, I. Bouligny +1 more
2023Blood1 citations
Semantic Scholar
The Molecular Landscape of Acute Myeloid Leukemia with Trisomy 8: A Comprehensive Cancer Center Analysis of 627 Patients
I. Bouligny, Graeme F Murray, T. Hồ, J. Gor +4 more
2023Blood1 citations Open access
Semantic Scholar
A Retrospective Comparison of Hypomethylating Agent in Combination with Venetoclax Versus Liposomal Daunorubicin and Cytarabine in Frontline Treatment of Acute Myeloid Leukemia
K. Maher, I. Bouligny
2021Blood1 citations Open access
Semantic Scholar
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
M. Sardar, R. Krishnadasan, K. Maher
2020Handbook of Hematologic Malignancies1 citations
Semantic Scholar
Fluconazole 200 mg Daily As Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Retrospective Review
K. Maher, A. McBride, C. Chen, Melissa Lim +6 more
20171 citations Open access
Semantic Scholar
Safety and Efficacy of Plerixafor on a Convenient Dose Schedule to Facilitate Outpatient Hematopoietic Stem Cell Collection for Autologous Hematopoietic Transplantation
C. Chen, A. Yeager, F. Anwer, A. McBride +2 more
20161 citations
Semantic Scholar
Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc‐fusion protein SL‐172154 (SIRPα‐Fc‐CD40L) in patients with higher‐risk myelodysplastic syndrome or acute myeloid leukemia
Naval G. Daver, A. Zeidan, A. Stein, J. Zeidner +21 more
2026Cancer0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

I. Bouligny×23
Invite
I. Bouligny — researcher profile on SciRah
Graeme F Murray×16
Invite
Graeme F Murray — researcher profile on SciRah
J. Gor×15
Invite
J. Gor — researcher profile on SciRah
T. Hồ×15
Invite
T. Hồ — researcher profile on SciRah

×13

Invite

Kyle Zacholski — researcher profile on SciRah

Steven Grant×8

Invite

Steven Grant — researcher profile on SciRah

Valerie Tran×8

Invite

Valerie Tran — researcher profile on SciRah

Invite

Yiwei Hang — researcher profile on SciRah

Yanal Alnimer×8

Invite

Yanal Alnimer — researcher profile on SciRah

Invite

C. Venn — researcher profile on SciRah

Invite

S. Grant — researcher profile on SciRah

S. Tantravahi×7

Invite

S. Tantravahi — researcher profile on SciRah